Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04760769 · ClinicalTrials.gov registry record · Phase 3
Open-label Trial in Parkinson's Disease (PD)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 992
- Enrollment target
NCT04760769 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 992 participants.
The verdict
NCT04760769, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 992 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
Interventions
- DRUG Tavapadon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 992 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04760769
The ClinicalTrials.gov registry entry for NCT04760769 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 992 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tavapadon is the first listed.
NCT04760769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04760769 about?
NCT04760769 is a clinical study titled "Open-label Trial in Parkinson's Disease (PD)". The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
What is the current status of trial NCT04760769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 992 participants. The study started on 2021-02-24. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT04760769?
The interventions under investigation include: Tavapadon (DRUG).
Who is sponsoring clinical trial NCT04760769?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.